# CAP-Ketamine for Antidepressant Resistant PTSD

> **NCT02655692** · PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 163 (actual)

## Conditions studied

- PTSD
- Posttraumatic Stress Disorder

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Placebo/Saline

## Key facts

- **NCT ID:** NCT02655692
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-18
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655692, "CAP-Ketamine for Antidepressant Resistant PTSD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02655692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*